Loading stock data…
$14.97-0.32 (-2.12%)
Dyne Therapeutics, Inc., a clinical-stage neuromuscular disease company, focuses on discovering and developing therapeutics for neuromuscular diseases in the United States.
Dyne Therapeutics, Inc. in the Healthcare sector is trading at $14.97 with a market capitalization of $4.9B. Wall Street consensus targets $35.73 (15 analysts), implying a +138.6% move over the next 12 months. The stock is currently near its 52-week low of $14.00, remaining 23.0% below its 200-day moving average. On fundamentals, Piotroski 3/9 flags weak fundamentals, Altman Z in the safe zone. The Whystock Score of 75/100 reflects bullish alignment across trend, valuation and analyst targets.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$181.66M↓ | -$125.28M↓ | -$116.13M↓ | -$113.89M↑ | -$115.79M |
| Net Income | -$178.56M↓ | -$120.85M↓ | -$111.95M↓ | -$108.04M↑ | -$110.86M |
Dyne Therapeutics, Inc., a clinical-stage neuromuscular disease company, focuses on discovering and developing therapeutics for neuromuscular diseases in the United States. The company is developing a portfolio of muscle disease therapeutics, includi...